

**CURRICULUM VITAE
LUCIO C. ROVATI**

Birthdate/place: 16th May, 1959 - Pavia (PV), Italy

Nationality: Italian

Marital status: Married; 1 daughter

Home address: Via Ramazzotti, 1
20052 Monza (Milano), Italy
Tel. ++39-039-2496554

Work address: Rottapharm Biotech S.r.l.
Via Valosa di Sopra 9
20900 Monza (MB), Italy
Tel. ++39-039-9066104
Fax ++39-039-9066161
Mobile ++39-335-202307
e-mail: lucio.rovati@rottapharmbiotech.com

Education:

1978/1985 - University of Milano(Italy), School of Medicine
Academic degree in Medicine and Surgery (M.D.), cum laude
(first class honors)

Postgraduate:

1985/1989 - University of Milano(Italy), School of Medicine
Postgraduate specialization in Clinical Pharmacology, cum laude (first
class honors)

Present position:

Chief Executive Officer
and
Chief Scientific Officer
Rottapharm Biotech S.r.l.
Monza - Italy

Main current responsibilities: Rottapharm Biotech is the R&D spin-off of the former Rottapharm pharmaceutical company. Rottapharm Biotech is involved in the discovery, research and development of new innovative drugs, both chemical or biological in nature. As the CEO and CSO, Dr. Rovati is responsible for all scientific and R&D activities of the company, with direct reporting from all operative functions: Medicinal Chemistry, Antibody Discovery & Protein Engineering, Pharmacology and Toxicology, Translational Sciences and Pharmacokinetics, Pharmaceutical Technology, Biostatistics, Clinical Research, Regulatory and Quality, Business Development, Scientific Liaison and Drug Safety.

Past appointments and industrial career:

2005-2014 – Chief Scientific Officer
and
Executive Medical Director
Rottapharm S.p.A. (Rottapharm | Madaus Group)
Monza - Italy

Main responsibilities: Head of the R&D Division of the international pharmaceutical group Rottapharm | Madaus, with direct reporting from all R&D departments (including Pharmacovigilance, for which he was the European Qualified Person for Pharmacovigilance), for the discovery, research and development of new original drugs.

Executive Medical Director of the Company and the Group, holding final responsibilities for all medical activities and of clinical research, with the inclusion of the Medical Departments in Cologne (Germany), Barcelona (Spain) and all branch offices.

2002-2004 – Head, Department of Clinical Pharmacology
and
Executive Medical Director
Rotta Research Laboratorium
(Rottapharm Group) – Monza (Milano) - Italy

1988/2001 – Chief, Department of Clinical Pharmacology.
Rotta Research Laboratorium - Monza (Milano) Italy.

Academic positions:

2003-2017 - Invited Professor of Clinical Pharmacology, University of Milano-Bicocca (Italy), School of Medicine

2009-2017 - Coordinator, Postgraduate Master in Pharmaceutical Medicine, University of Milano-Bicocca (Italy), School of Medicine

2001/2002 - Invited Professor of Clinical Pharmacology, University of Naples – Federico II (Italy), School of Pharmacy

1999/2000 - Invited Professor of Pharmacology, University of Parma (Italy), School of Pharmacy.

1998/2002 - Senior Lecturer in Clinical Pharmacology at the University of Milano (Italy), Postgraduate School of Medicine.

Previous positions:

1984/1988 - Research fellow in the Department of Medical Pharmacology, Chemotherapy and Toxicology, Chair of Pharmacology (Director: Prof. P. Mantegazza), University of Milano(Italy), School of Medicine.

1982/1986 - Medical student and then attending physician (1985/1986) in the Department of Internal Medicine (Director: Prof. C. Rugarli), S. Raffaele Hospital - University of Milano (Italy), School of Medicine.

Summary of academic and industrial experience:

- Clinical experience in Internal Medicine
- Laboratory experience on in vitro and in vivo pharmacology, in particular of the Central Nervous System, Digestive System and Musculoskeletal System. Main areas of experience include: pharmacology of peptide hormones and neuropeptides, with special regard to investigations in the field of gastrointestinal motility and secretions, mechanisms of analgesia, stress and anxiety disorders, in vitro and in vivo models of degenerative and inflammatory joint diseases.
- Wide clinical research experience in the past and present positions for the direction (planning, performance, reporting) of phase 1 (including pharmacokinetics) to phase 3 and 4 clinical studies for the development of new original drugs. Selected areas of specific experience include:
 - ✓ Gastroenterology, in particular: drugs for the control of gastrointestinal motility and sensitivity, gastric acid secretion and peptic ulcer, pancreatic exocrine secretion and acute/chronic pancreatitis, viral hepatitis.
 - ✓ Epatology, in particular: drugs for the treatment of infectuous diseases (Hepatitis C), liver inflammatory, degenerative (NAFLD/NASH) and fibrotic diseases.
 - ✓ Rheumatology, in particular: drugs for the control of symptoms and disease progression in osteoarthritis and for the prevention and treatment of osteoporosis; Disease-Modifying Anti-Rheumatic Agents (DMARDs) in rheumatoid arthritis; non-steroidal antiinflammatory drugs.
 - ✓ Gynecology, in particular: hormone replacement therapy and oral contraceptives.
 - ✓ Bronchopneumology, in particular: drugs for the treatment of asthma and allergic rhinitis.
 - ✓ Neurology/Psychiatry and Central Nervous System, in particular: drugs for the treatment of panic and anxiety disorders, schizophrenia depressive syndromes, dementia and neurodegenerative conditions; central and peripheral analgesics.
 - ✓ Cardiology and Internal Medicine, in particular: drugs for the treatment of ischemic heart disease and hypertension; therapeutic agents for dyslipidemie and dysglycemie.
- Development of high quality dietary supplements for the prevention and treatment of disorders in the same areas above.
- Teaching experience as an Academic Professor includes lessons of general and clinical pharmacology to students in Medicine and other biological disciplines, and in postgraduate courses and Master courses. Additional teaching experience includes scientific training to industrial drug representatives, lectures in "state of the art" courses on selected topics to academic and industrial specialists.

Membership of Scientific Societies:

American College of Rheumatology;
American Gastroenterological Association;
European Society of Neurogastroenterology and Motility;
European Menopause and Andropause Society;
European Society for Gynecologic and Obstetric Investigation;
Group for the Respect of Ethics and Excellence in Science;
International Association of Pancreatology;

International Osteoporosis Foundation;
Osteoarthritis Research Society International;
Society for Medicines Research;
Italian Association for the Study of Pancreas;
Italian Society of Gastroenterology;
Italian Society for Osteoporosis, Mineral Metabolism and Skeletal Diseases;
Italian Society of Pharmaceutical Sciences;
Italian Society of Pharmacology;
Italian Society of Rheumatology.

Publications and related scientific activity

Author or co-author of over 180 full papers published in peer review international scientific journals (with an H-index =37) and of 15 book chapters. Related scientific activity includes authorship of over 400 abstracts and selected/invited presentations in international congresses.

PUBLICATIONS

Original papers, leading articles, major reviews in peer review international journals

1. Makovec F, Bani M, Chistè R, Revel L, Rovati LC, Setnikar I. DIFFERENT PERIPHERAL AND CENTRAL ANTAGONISTIC ACTIVITY OF NEW GLUTARAMIC ACID DERIVATIVES ON SATIETY INDUCED BY CHOLECYSTOKININ IN RATS.
Regul. Pept. **16**, 281-290, **1986**
2. Collado-Escobar D, Rovati LC, Ganzetti I, Cocchi D, Panerai AE, Li CH. THE BETA-ENDORPHIN-INDUCED SECRETION OF GROWTH HORMONE BUT NOT OF PROLACTIN IS INHIBITED BY AN ENDOGENOUS OPIOID ANTAGONIST.
Eur. J. Pharmacol. **129**, 385-387, **1986**
3. Makovec F, Bani M, Chistè R, Revel L, Rovati LC, Rovati LA. DIFFERENTIATION OF CENTRAL AND PERIPHERAL CHOLECYSTOKININ RECEPTORS BY NEW GLUTARAMIC ACID DERIVATIVES WITH CHOLECYSTOKININ-ANTAGONISTIC ACTIVITY.
Arzneim.-Forsch. **36**, 98-102, **1986**
4. Makovec F, Bani M, Cereda R, Chistè R, Revel L, Rovati LC, Setnikar I, Rovati LA. PROTECTIVE EFFECT OF CR 1409 (CHOLECYSTOKININ ANTAGONIST) ON EXPERIMENTAL PANCREATITIS IN RATS AND MICE.
Peptides **7**, 1159-1164, **1986**
5. Panerai AE, Rovati LC, Cocco E, Sacerdote P, Mantegazza P. DISSOCIATION OF TOLERANCE AND DEPENDENCE TO MORPHINE: A POSSIBLE ROLE FOR CHOLECYSTOKININ.
Brain Res. **410**, 52-60, **1987**
6. Makovec F, Bani M, Cereda R, Chistè R, Pacini MA, Revel L, Rovati LC. ANTISPASMODIC ACTIVITY ON THE GALLBLADDER OF THE MOUSE OF CR 1409 (LORGLUMIDE) A POTENT ANTAGONIST OF PERIPHERAL CCK.
Pharmacol. Res. Commun. **19**, 41-51, **1987**
7. Makovec F, Bani M, Cereda R, Chistè R, Pacini MA, Revel L, Rovati LA, Rovati LC, Setnikar I. PHARMACOLOGICAL PROPERTIES OF LORGLUMIDE AS A MEMBER OF A NEW CLASS OF CHOLECYSTOKININ ANTAGONISTS.
Arzneim.-Forsch. **37**, 1265-1268, **1987**
8. Panerai AE, Rovati LC, Bianchi M, Bareggi SR, Mantegazza P. EFFECT OF A CHOLECYSTOKININ ANTAGONIST ON SOME EFFECTS OF DIAZEPAM.
Neuropharmacology **26**, 1285-1287, **1987**
9. Setnikar I., Bani M, Cereda R, Chistè R, Makovec F, Pacini MA, Revel L, Rovati LC, Rovati LA. PHARMACOLOGICAL CHARACTERISATION OF A NEW POTENT AND SPECIFIC

- NONPOLYPEPTIDIC CHOLECYSTOKININ ANTAGONIST.
Arzneim.-Forsch. **37**, 703-707, **1987**
10. Bianchi M, Rovati LC, Panerai AE.
ANALGESIA DA CLONIDINA: RUOLO DEI RECETTORI OPPIACEI.
Algos **4**, 17-20, **1987**
 11. Pagnoni B, Ortalli G, Rovati LC, Tiengo M.
POSSIBLE POTENTIATION OF MORPHINE ANALGESIA BY PROGLUMIDE.
Minerva Anesthesiol. **54**, 131-136, **1988**
 12. Hoosein NM, Kiener PA, Curry RC, Rovati LC, McGilbra DK, Brattain MG.
ANTIPROLIFERATIVE EFFECTS OF GASTRIN RECEPTOR ANTAGONISTS AND
ANTIBODIES TO GASTRIN ON HUMAN COLON CARCINOMA CELL LINES.
Cancer Res. **48**, 7179-7183, **1988**
 13. Balboni B, Valenti P, Da Re P, Rovati LC, Makovec F.
CALCIUM ANTAGONISTS: VINYLOGUES AND BIVALENT LIGANDS RELATED TO
NIFEDIPINE.
Pharmazie **43**, 318-320, **1988**
 14. Setnikar I, Chistè R, Makovec F, Rovati LC, Warrington SJ.
PHARMACOKINETICS OF LOXIGLUMIDE AFTER SINGLE INTRAVENOUS OR ORAL
DOSES IN MAN.
Arzneim.-Forsch. **38**, 716-720, **1988**
 15. Rovati LC, Sacerdote P, Bianchi M, Panerai AE.
CHRONIC INTRATHECAL CANNULATION AFFECTS HYPOTHALAMIC BETA-
ENDORPHIN AND MET-ENKEPHALIN CONCENTRATIONS.
Pharmacol. Methods **19**, 85-88, **1988**
 16. Meyer BM, Werth BA, Beglinger C, Hildebrand P, Jansen JB, Zach D, Rovati LC,
Stalder GA.
ROLE OF CHOLECYSTOKININ IN REGULATION OF GASTROINTESTINAL MOTOR
FUNCTIONS.
Lancet **2**, 12-15, **1989**
 17. Douglas BR, Woutersen RA, Jansen JB, Rovati LC, Lamers CB.
STUDY INTO THE ROLE OF CHOLECYSTOKININ IN BOMBESIN-STIMULATED
PANCREATIC GROWTH IN RATS AND HAMSTERS.
Eur. J. Pharmacol. **161**, 209-214, **1989**
 18. Douglas BR, Woutersen RA, Jansen JB, De Jong AJ, Rovati LC, Lamers CB.
MODULATION BY CR 1409 (LORGLUMIDE), A CHOLECYSTOKININ RECEPTOR
ANTAGONIST, OF TRYPSIN INHIBITOR-ENHANCED GROWTH OF AZASERINE-
INDUCED PUTATIVE PRENEOPLASTIC LESIONS IN RAT PANCREAS.
Cancer Res. **49**, 2438-2441, **1989**
 19. Adler G, Reinshagen M, Koop I, Goke B, Schafmayer A, Rovati LC, Arnold R.
DIFFERENTIAL EFFECTS OF ATROPINE AND A CHOLECYSTOKININ RECEPTOR
ANTAGONIST ON PANCREATIC SECRETION.
Gastroenterology **96**, 1158-1164, **1989**

20. Douglas BR, Woutersen RA, Jansen JB, De Jong AJ, Rovati LC, Lamers CB.
INFLUENCE OF CHOLECYSTOKININ ANTAGONIST ON THE EFFECTS OF
CHOLECYSTOKININ AND BOMBESIN ON AZASERINE-INDUCED LESIONS IN RAT
PANCREAS.
Gastroenterology **96**, 462-469, **1989**
21. Setnikar I, Chistè R, Giacobelli G, Rovati LC.
PHARMACOKINETICS AND TOLERANCE OF REPEATED ORAL DOSES OF
LOXIGLUMIDE.
Arzneim.-Forsch. **39**, 1454-1459, **1989**
22. Konturek JW, Konturek SJ, Kurek A, Bogdal J, Oleksy, Rovati LC.
CCK RECEPTOR ANTAGONISM BY LOXIGLUMIDE AND GALLBLADDER
CONTRACTIONS IN RESPONSE TO CHOLECYSTOKININ, SHAM FEEDING AND
ORDINARY FEEDING IN MAN.
Gut **30**, 1136-1142, **1989**
23. Niederau C, Heintges T, Rovati LC, Strohmeyer G.
EFFECTS OF LOXIGLUMIDE ON GALLBLADDER EMPTYING IN HEALTHY
VOLUNTEERS.
Gastroenterology **97**, 1331-1336, **1989**
24. Bianchi M, Brini A, Rovati LC, De Giuli-Morghen C, Panerai AE.
POSSIBLE INVOLVEMENT OF DYNORPHIN IN CLONIDINE INDUCED ANALGESIA.
Med. Sci. Res. **17**, 351-352, **1989**
25. Rovati LC.
LE TERAPIE FARMACOLOGICHE NELL'ARTROPATIA DEGENERATIVA:
SITUAZIONE ATTUALE E PROSPETTIVE FUTURE.
La Riabilitazione **22**, 233-240, **1989**
26. Brini A, De Giuli Morghen C, Bianchi M, Rovati LC, Panerai AE.
PROOPIOMELANOCORTIN, PREPROENKEPHALIN-A AND PREPRO-
CHOLECYSTOKININ mRNA IN THE HYPOTHALAMUS OF CCl₄-TREATED RATS
J. of Neuroendocrinology **1**, 235-236, **1989**
27. Bianchi M, Rovati LC, Sacerdote P, Mantegazza P, Panerai AE.
EFFECT OF DRUGS BELONGING TO DIFFERENT CLASSES OF CALCIUM CHANNEL
BLOCKERS ON EXPERIMENTAL SEIZURES INDUCED BY THE CALCIUM CHANNEL
AGONIST BAY K 8644.
Neuroscience Res. Comm. **6**, 157-162, **1990**
28. Jansen JB, De Jong AJ, Singer MV, Niebel W, Rovati LC, Lamers CB.
ROLE OF CHOLECYSTOKININ IN BOMBESIN- AND MEAL-STIMULATED
PANCREATIC POLYPEPTIDE SECRETION IN DOGS.
Dig. Dis. Sci. **35**, 1073-1077, **1990**
29. Rovati LC, Sacerdote P, Fumagalli P, Bianchi M, Mantegazza P, Panerai AE.
BENZODIAZEPINES AND THEIR ANTAGONISTS INTERFERE WITH OPIOD-

- DEPENDENT STRESS-INDUCED ANALGESIA.
Pharmacol. Biochem. Behav. **36**, 123-126, **1990**
30. Hildebrand P, Beglinger C, Gyr K, Jansen JB, Rovati LC, Zuercher M, Lamers CB, Setnikar I, Stalder GA.
EFFECTS OF A CHOLECYSTOKININ RECEPTOR ANTAGONIST ON INTESTINAL PHASE OF PANCREATIC AND BILIARY RESPONSES IN MAN.
Clin. Invest. **85**, 640-646, **1990**
31. Douglas BR, Woutersen RA, Jansen JB, Rovati LC, Lamers CB.
COMPARISON OF THE EFFECT OF LORGLUMIDE ON PANCREATIC GROWTH STIMULATED BY CAMOSTATE IN RAT AND HAMSTER.
Life Sci. **46**, 281-286, **1990**
32. Schmidt WE, Creutzfeldt W, Höcker M, Roy Choudhury A, Nustede R, Schleser A, Nitsche R, Rovati LC, Schafmayer A, Fölsch UR.
CHOLECYSTOKININ RECEPTOR ANTAGONIST LOXIGLUMIDE: INFLUENCE ON BILIO-PANCREATIC SECRETION AND GASTROINTESTINAL HORMONES IN MAN.
Digestion **46**, 232-239, **1990**
33. Adler G, Reinshagen M, Beglinger C, Rovati LC, Arnold R.
EFFECT OF A CHOLECYSTOKININ ANTAGONIST, LOXIGLUMIDE, ON PANCREATIC SECRETION IN PATIENTS WITH CHRONIC PANCREATITIS.
Biomedical Res. **11**, 151-156, **1990**
34. Konturek SJ, Kwiecien N, Obtulowicz W, Kopp B, Olesky J, Rovati L.C.
CHOLECYSTOKININ IN THE INHIBITION OF GASTRIC SECRETION AND GASTRIC EMPTYING IN HUMANS.
Digestion **45**, 1-8, **1990**
35. Malesci A, De Fazio C, Festorazzi S, Bonato C, Valentini A, Tacconi M, Rovati LC, Setnikar I.
EFFECT OF LOXIGLUMIDE ON GALLBLADDER CONTRACTILE RESPONSE TO CERULEIN AND FOOD IN HUMANS.
Gastroenterology **98**, 1307-1310, **1990**
36. Meijers M., van Garderen-Hoetmer A., Lamers C.B., Rovati L.C., Jansen J.B., Woutersen R.A.
ROLE OF CHOLECYSTOKININ IN THE DEVELOPMENT OF BOP-INDUCED PANCREATIC LESIONS IN HAMSTERS.
Carcinogenesis **11**, 2223-2226, **1990**
37. Schmidt WE, Creutzfeldt W, Schleser A, Roy Choudhury A, Nustede R, Höcker M, Nitsche R, Sostmann H, Rovati LC, Fölsch UR.
ROLE OF CCK IN REGULATION OF PANCREATICOBILIARY FUNCTIONS AND GI MOTILITY IN HUMANS: EFFECTS OF LOXIGLUMIDE.
Amer. J. Physiol., **260**, G197-G206, **1991**
38. Meijers M., van Garderen-Hoetmer A., Lamers C.B., Rovati L.C., Jansen J.B., Woutersen R.A.
EFFECTS OF BOMBESIN ON THE DEVELOPMENT OF N-NITROSOBIS(2-

OXOPROPYL)AMINE-INDUCED PANCREATIC LESIONS IN HAMSTERS.

Cancer Letters 59, 45-50, **1991**

39. Jebbink M.C., Jansen J.B., Mooy D.M., Rovati L.C., Lamers C.B.
EFFECT OF THE SPECIFIC CHOLECYSTOKININ-RECEPTOR ANTAGONIST LOXIGLUMIDE ON BOMBESIN STIMULATED PANCREATIC ENZYME SECRETION IN MAN.
Regul. Peptides 32, 361-368, **1991**
40. Piolti R., Appollonio I., Cocco E., Ferrarese C., Frattola L., Rovati L., Panerai A.E.
TREATMENT OF PARKINSON'S DISEASE WITH PROGLUMIDE, A CCK ANTAGONIST.
Neurology 41, 749-750, **1991**
41. Adler G., Beglinger C., Braun U., Reinshagen M., Koop I., Schafmayer A., Rovati L.C., Arnold R.
INTERACTION OF THE CHOLINERGIC SYSTEM AND CHOLECYSTOKININ IN THE REGULATION OF ENDOGENOUS AND EXOGENOUS STIMULATION OF PANCREATIC SECRETION IN HUMANS.
Gastroenterology 100, 537-543, **1991**
42. Rovati LC.
PERSPECTIVES OF CCK ANTAGONISTS IN PANCREATIC RESEARCH AND CLINICAL USE.
Int. J. Pancreatology, 8, 215-226, **1991**
43. De Jong AJL, Singer MV, Jansen JBMJ, Niebel W, Rovati LC, Lamers CBHW.
EFFECT OF THE CHOLECYSTOKININ-RECEPTOR ANTAGONIST LORGLUMIDE ON PANCREATIC ENZYME SECRETION STIMULATED BY BOMBESIN, FOOD, AND CAERULEIN, GIVING SIMILAR PLASMA CHOLECYSTOKININ CONCENTRATIONS IN THE DOG.
Gut, 32, 215-219, **1991**
44. Fried M, Erlacher U, Schwizer W, Löchner, Koerfer J, Beglinger C, Jansen JB, Lamers CB, Harder F, Bischof-Delaloye A, Stalder GA, Rovati LC.
ROLE OF CHOLECYSTOKININ IN THE REGULATION OF GASTRIC EMPTYING SECRETION IN HUMANS.
Gastroenterology, 101, 503-511, **1991**
45. Schmidt WE, Creutzfeldt W, Höcker M, Nustede R, Roy Choudhury A, Schleser A, Rovati LC, Fölsch UR.
CHOLECYSTOKININ RECEPTOR ANTAGONIST LOXIGLUMIDE MODULATES PLASMA LEVELS OF GASTRO-ENTERO-PANCREATIC HORMONES IN MAN.
Eur. J. Clin. Invest., 21, 501-511, **1991**
46. Meijers M, van Garderen-Moetmer A, Lamers CBHW, Rovati LC, Jansen JBMJ, Woutersen RA.
EFFECTS OF THE SYNTHETIC TRYPSIN INHIBITOR CAMOSTATE ON THE DEVELOPMENT OF N-NITROSOBIS(2-OXOPROPYL)AMINE-INDUCED PANCREATIC LESIONS IN HAMSTERS.
Cancer Letters, 60, 205, 211, **1991**

47. Makovec F, Peris W, Revel L, Giovanetti R, Mennuni L, Rovati LC. STRUCTURE ANTIGASTRIN ACTIVITY RELATIONSHIPS OF NEW R-4-BENZAMIDO-5-OXO-PENTANOIC ACID DERIVATIVES.
J. Med. Chem., **35**, 28-38, **1992**
48. Niederau C, Schwarzendrube J, Lüthen R, Niederau M, Strohmeyer G, Rovati L. EFFECTS OF CHOLECYSTOKININ RECEPTOR BLOCKADE ON CIRCULATING CONCENTRATIONS OF GLUCOSE, INSULIN, C-PEPTIDE, AND PANCREATIC POLYPEPTIDE AFTER VARIOUS MEALS IN HEALTHY HUMAN VOLUNTEERS.
Pancreas, **7**, 1-10, **1992**
49. Drewe J., Gadiant A., Rovati L.C. ROLE OF CIRCULATING CHOLECYSTOKININ IN CONTROL OF FAT-INDUCED INHIBITION OF FOOD INTAKE IN HUMANS.
Gastroenterology, **102**, 1654-1659, **1992**
50. Revel L., Ferrari F., Makovec F., Rovati L.C. CHARACTERIZATION OF ANTIGASTRIN ACTIVITY IN VIVO OF CR 2194, A NEW R-4-BENZAMIDO-5-OXO-PENTANOIC ACID DERIVATIVE.
Eur. J. Pharmacology, **216**, 217-224, **1992**
51. Watson S.A., Crosbee D.M., Morris D.L., Robertson J.F.R., Makovec F., Rovati L.C., Hardcastle J.D. THERAPEUTIC EFFECT OF THE GASTRIN RECEPTOR ANTAGONIST, CR 2093 ON GASTROINTESTINAL TUMOUR CELL GROWTH.
Br. J. Cancer, **65**, 879-883, **1992**
52. Malesci A., De Fazio C., Festorazzi S., Bonato C., Valentini A., Tacconi M., Bekkering M., Giacobelli G., D'Amato M., Rovati L.C. DOSE-RESPONSE EFFECTS OF ORAL LOXIGLUMIDE ON POSTPRANDIAL GALLBLADDER EMPTYING IN MAN.
Arzneim.-Forsch., **42**, 1359-1362, **1992**
53. Makovec F., Peris W., Revel L., Giovanetti R., Redaelli D., Rovati L.C. ANTIALLERGIC AND CYTOPROTECTIVE ACTIVITY OF NEW N-PHENYLBENZAMIDO ACID DERIVATIVES.
Med. Chem., **35**, 3633-3640, **1992**
54. Revel L., Colombo S., Ferrari F., Folco G., Rovati L.C. CR 2039, A NEW BIS-(1H-TETRAZOL-5-YL)PHENYLBENZAMIDE DERIVATIVE WITH POTENTIAL FOR THE TOPICAL TREATMENT OF ASTHMA
Eur. J. Pharmacol., **229**, 45-53, **1992**
55. Rovati L.C. CLINICAL RESEARCH IN OSTEOARTHRITIS: DESIGN AND RESULTS OF SHORT-TERM AND LONG-TERM TRIALS WITH DISEASE-MODIFYING DRUGS.
Int. J. Tiss. Reac., **XIV**, 243-251, **1992**
56. Jebbink M.C., Masclee A.A., van der Kleij F.G., Schipper J., Rovati L.C., Jansen J.B., Lamers C.B. EFFECT OF LOXIGLUMIDE AND ATROPINE ON ERYTHROMYCIN-INDUCED

- REDUCTION IN GALLBLADDER VOLUME IN HUMAN SUBJECTS.
Hepatology, **16**, 937-942, **1992**
57. Jebbink M.C., Lamers C.B., Mooy D.M., Rovati L.C., Jansen J.B.
EFFECT OF LOXIGLUMIDE ON BASAL AND GASTRIN- AND BOMBESIN-
STIMULATED GASTRIC ACID AND SERUM GASTRIN LEVELS.
Gastroenterology, **103**, 1215-1220, **1992**
58. Meijers M., Appel M.J., van Garderen-Hoetmer A., Lamers C.B., Rovati L.C.,
Jansen J.B., Woutersen R.A.
EFFECTS OF CHOLECYSTOKININ AND BOMBESIN ON DEVELOPMENT OF
AZASERINE-INDUCED PANCREATIC TUMOURS IN RATS: MODULATION BY THE
CHOLECYSTOKININ RECEPTOR ANTAGONIST LORGLUMIDE.
Carcinogenesis, **13**, 1525-1528, **1992**
59. Appel M.J., Meijers M., van Garderen-Hoetmer A., Lamers C.B., Rovati L.C., Sprij-
Mooij D., Jansen J.B., Woutersen R.A.
ROLE OF CHOLECYSTOKININ IN DIETARY FAT-PROMOTED AZASERINE-
INDUCED PANCREATIC CARCINOGENESIS IN RATS.
Br. J. Cancer, **66**, 46-50, **1992**
60. Masclee A.A.M., Jansen J.B.M.J., Rovati L.C. and Lamers C.B.H.W.
EFFECT OF CHOLESTYRAMINE AND CHOLECYSTOKININ RECEPTOR
ANTAGONIST CR 1505 (LOXIGLUMIDE) ON LOWER ESOPHAGEAL SPHINCTER
PRESSURE IN MAN.
Dig. Dis. and Sciences, **38**, 1889-1892, **1993**
61. Meier R., Beglinger C., Thumshirn M., Meyer B., Rovati L.C., Giacobelli G.,
D'Amato M., Gyr K.
THERAPEUTIC EFFECTS OF LOXIGLUMIDE, A CHOLECYSTOKININ ANTAGONIST,
ON CHRONIC CONSTIPATION IN ELDERLY PATIENTS: A PROSPECTIVE,
RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL.
Gastrointest. Mot., **5**, 129-135, **1993**
62. Jebbink M.C., Jansen J.B., van der Kleij F.G., Mooy D.M., Rovati L.C., Lamers C.B.

EFFECT OF DUODENAL JUICE ON BOMBESIN-STIMULATED CHOLECYSTOKININ
RELEASE DURING LOXIGLUMIDE ADMINISTRATION IN MAN.
Eur. J. Clinical Investigation **23**, 529-533, **1993**
63. Lieveise R.J., Jansen J.B., van de Zwan A., Samson L., Masclee A.A., Rovati L.C.,
Lamers C.B.
BOMBESIN REDUCES FOOD INTAKE IN LEAN MAN BY A CHOLECYSTOKININ-
INDEPENDENT MECHANISM.
J. Clin. Endocrinol. & Metabolism, **76**, 1495-1498, **1993**
64. Reichelt A., Förster K.K., Fischer M., Rovati L.C., Setnikar I.
EFFICACY AND SAFETY OF INTRAMUSCULAR GLUCOSAMINE SULFATE IN
OSTEOARTHRITIS OF THE KNEE.
Arzneim.-Forsch./Drug Res. **44**, 1, 75-80, **1994**

65. Noack W., Fischer M., Förster K.K., Rovati L.C., Setnikar I.
GLUCOSAMINE SULFATE IN OSTEOARTHRITIS OF THE KNEE.
Osteoarthritis and Cartilage 2, 51-59, **1994**
66. Müller-Fassbender H., Bach G.L., Haase W., Rovati L.C., Setnikar I.
GLUCOSAMINE SULFATE COMPARED TO IBUPROFEN IN OSTEOARTHRITIS OF
THE KNEE.
Osteoarthritis and Cartilage 2, 61-69, **1994**
67. Barrow L., Blackshaw P.E., Wilson C.G., Rovati L.C., Spiller R.C.
SELECTIVE SLOWING OF PROXIMAL COLON TRANSIT IN IRRITABLE BOWEL
SYNDROME BY THE CHOLECYSTOKININ-RECEPTOR ANTAGONIST,
LOXIGLUMIDE.
Eur. J. Gastroenterol. & Hepatology 6, 381-387, **1994**
68. Sperti C., Militello C., Rovati L.C., Behboo R., Khajeturian E., Perasole A., Alaggio
R., Pedrazzoli S.
EFFECT OF CHOLECYSTOKININ ANALOGUE CAERULEIN AND
CHOLECYSTOKININ ANTAGONIST LORGLUMIDE ON PANCREATIC
CARCINOGENESIS IN THE RAT
J. Surg. Oncology 57, 11-16, **1994**
69. Lieveise R.J., Jansen J.B., Masclee A.A., Rovati L.C., Lamers C.B.
EFFECT OF A LOW DOSE OF INTRADUODENAL FAT ON SATIETY IN HUMANS:
STUDIES USING THE TYPE A CHOLECYSTOKININ RECEPTOR ANTAGONIST
LOXIGLUMIDE
Gut 35, 501-505, **1994**
70. Verhulst M.L., Gielkens H.A., Hopman W.P., van Schaik A., Tangerman A., Rovati
L.C., Jansen J.B.
LOXIGLUMIDE INHIBITS CHOLECYSTOKININ STIMULATED SOMATOSTATIN
SECRETION AND SIMULTANEOUSLY ENHANCES GASTRIC ACID SECRETION IN
HUMANS.
Regul. Peptides 53, 185-193, **1994**
71. French S.J., Bergin A., Sepple C.P., Read N.W., Rovati L.C.
THE EFFECTS OF LOXIGLUMIDE ON FOOD INTAKE IN NORMAL WEIGHT
VOLUNTEERS.
Int. J. of Obesity & Related Metabolic Disorders 18, 738-741, **1994**
72. D'Amato M., Rovati L.C.
CCK-A ANTAGONISTS: WHICH AND HOW
Eur. J. Clin. Invest. 25, 213-214, **1995**
73. Lieveise R.J., Masclee A.A., Jansen J.B., Rovati L.C., Lamers C.B.
SATIETY EFFECTS OF THE TYPE A CCK RECEPTOR ANTAGONIST LOXIGLUMIDE
IN LEAN AND OBESE WOMEN
Biol. Psychiatry 37, 331-335, **1995**
74. Lieveise R.J., Jansen J.B., Jebbink M.C., Masclee A.A., Rovati L.C., Lamers C.B.
EFFECTS OF SOMATOSTATIN AND LOXIGLUMIDE ON GALLBLADDER MOTILITY
Eur. J. Clin. Pharmacol. 47, 489-492, **1995**

75. Miglio F., Rovati L.C., Santoro A.
EFFICACY OF GLUCURONATES VERSUS PLACEBO IN CHRONIC HEPATITIS: A
RANDOMIZED, DOUBLE-BLIND STUDY.
Advances in Therapy 12, 299-312, **1995**
76. Gambacciani M., Spinetti A., Taponeco F., Piaggese L., Cappagli B., Ciaponi M.,
Rovati L.C., Genazzani A.R.
TREATMENT OF POSTMENOPAUSAL VERTEBRAL OSTEOPENIA WITH
MONOFLUOROPHOSPHATE: A LONG-TERM CALCIUM-CONTROLLED STUDY.
Osteoporosis Int. 5, 467-471, **1995**
77. Gambacciani M., Spinetti A., Cappagli B., Ciaponi M., Gallo R., Rovati L.C.,
Genazzani A.R.
EFFECTS OF A LOW-DOSE MONOFLUOROPHOSPHATE AND TRANSDERMAL
OESTRADIOL ON POSTMENOPAUSAL VERTEBRAL BONE LOSS.
Eur. Menopause J. 2, 16-20, **1995**
78. Setnikar I., Rovati L.C., Vens-Cappell B., Hilgenstock C.
BIOAVAILABILITY OF ESTRADIOL FROM TWO TRANSDERMAL PATCHES.
Arzneim.-Forsch. 46, 307-310, **1996**
79. Setnikar I., Rovati L.C., Vens-Cappell B., Hilgenstock C.
PHARMACOKINETICS OF ESTRADIOL AND OF ESTRONE DURING REPEATED
TRANSDERMAL OR ORAL ADMINISTRATION OF ESTRADIOL.
Arzneim.-Forsch. 46, 766-773, **1996**
80. D'Amato M., Rovati L.C.
CHOLECYSTOKININ-A RECEPTOR ANTAGONISTS: THERAPIES FOR
GASTROINTESTINAL DISORDERS.
Exp. Opin. Invest. Drugs 6, 819-836, **1997**
81. Mesquita M.A., Thompson D.G., Troncon L.E.A., D'Amato M., Rovati L.C., Barlow
J.
EFFECT OF CHOLECYSTOKININ-A RECEPTOR BLOCKADE ON LIPID-INDUCED
GASTRIC RELAXATION IN HUMANS.
Am. J. Physiol. 273, G118-G123, **1997**
82. Setnikar I., Rovati L.C., Vens-Cappell B., Hilgenstock C.
PHARMACOKINETICS OF ESTRADIOL AND OF ESTRONE DURING APPLICATION
OF A NEW 7-DAY ESTRADIOL TRANSDERMAL PATCH WITH ACTIVE MATRIX.
Arzneim.-Forsch. 48 (I), 3, 275-285, **1998**
83. Qiu G.X., Gao S.N., Giacobelli G., Rovati L.C., Setnikar I.
EFFICACY AND SAFETY OF GLUCOSAMINE SULFATE VERSUS IBUPROFEN IN
PATIENTS WITH KNEE OSTEOARTHRITIS
Arzneim.-Forsch. 48 (I), 5, 469-474, **1998**
84. Setnikar I., Rovati L.C., Schmid K., Vens-Cappell B., Barkworth M.F.
BIOAVAILABILITY AND PHARMACOKINETIC CHARACTERISTICS OF TWO
MONOFLUOROPHOSPHATE PREPARATIONS WITH CALCIUM SUPPLEMENT
Arzneim.-Forsch. 48 (II), 12, 1172-1178, **1998**

85. Rozenbaum H., Birkhäuser M.H.:
ACTIVE MATRIX TRANSDERMAL PATCHES: TODAY'S SOLUTION TO
CONTROVERSIES IN HRT
Menopause Review, 3, Specia Issue 1, 1998
86. Bassleer C., Rovati L.C., Franchimont P.
STIMULATION OF PROTEOGLYCAN PRODUCTION BY GLUCOSAMINE SULFATE
IN CHONDROCYTES ISOLATED FROM HUMAN OSTEOARTHRITIC ARTICULAR
CARTILAGE IN VITRO.
Osteoarthritis Cart., 6, 427-434, 1998
87. Reginster J.Y., Meurmans L., Zegels B., Rovati L.C., Minne H.W., Giacovelli G.,
Taquet A.N., Setnikar I., Collette J., Gosset C.
THE EFFECT OF SODIUM MONOFLUOROPHOSPHATE PLUS CALCIUM ON
VERTEBRAL FRACTURE RATE IN POSTMENOPAUSAL WOMEN WITH MODERATE
OSTEOPOROSIS
Ann. Int. Med. 129, 1-8, 1998
88. Ringe J.D., Dorst A., Kipshoven C., Rovati L.C., Setnikar I.
AVOIDANCE OF VERTEBRAL FRACTURES IN MEN WITH IDIOPATHIC
OSTEOPOROSIS BY A THREE YEAR THERAPY WITH CALCIUM AND LOW-DOSE
INTERMITTENT MONOFLUOROPHOSPHATE
Osteoporosis Int., 8, 47-52, 1998
89. Beltinger J., Hildebrand P., Drewe J., Christ A., Hlobil K., Ritz M., D'Amato M.,
Rovati L., Beglinger C.
EFFECTS OF SPIROGLUMIDE, A GASTRIN RECEPTOR ANTAGONIST, ON ACID
SECRETION IN HUMANS.
Eur J Clinical Investigation, 29, 153-159, 1999
90. Rovati L.C.
RADIOGRAPHIC ASSESSMENT. INTRODUCTION: EXISTING METHODOLOGY.
Osteoarthritis Cartilage, 7, 427-429, 1999
91. Setnikar I., Rovati L.C., Santoro A., Guillaume M., Mignon A., Renoux A. and
Gualano V.
ESTRADIOL AND ESTRONE PLASMA LEVELS DURING APPLICATION OF THREE
STRENGTHS OF A 7-DAY ESTRADIOL TRANSDERMAL PATCH.
Arzneim.-Forsch. 49 (II), 708-715, 1999
92. Rovati L.C., Schmid K., Giacovelli G., Bonn M., Setnikar I., Wolff F., Genazzani
A.R.
EFFICACY ON CLIMACTERIC SYMPTOMS OF A NEW ESTRADIOL TRANSDERMAL
PATCH WITH ACTIVE MATRIX IN COMPARISON WITH A REFERENCE RESERVOIR
PATCH.
Arzneim.-Forsch. 49 (II), 933-943, 1999
93. Cagnacci A., Rovati L.C., Zanni A., Malmusi S., Facchinetti F. and Volpe A.
PHYSIOLOGICAL DOSES OF ESTRADIOL DECREASE NOCTURNAL BLOOD
PRESSURE IN NORMOTENSIVE POSTMENOPAUSAL WOMEN.
Am. J. Physiol 276, H1355-H1360, 1999

94. Rovati L.C., Annefeld M., Giacobelli G., Schmid K. and Setnikar I.
GLUCOSAMINE IN OSTEOARTHRITIS.
Lancet **354**, 1640, **1999**
95. Matzinger D., Gutzwiller J.P., Drewe J., Orban A., Engel R., D'Amato M., Rovati L.C. and Beglinger C.
INHIBITION OF FOOD INTAKE IN RESPONSE TO INTESTINAL LIPID IS MEDIATED BY CHOLECYSTOKININ IN HUMANS.
Am J Physiol **277**, R1718-R1724, **1999**
96. Piccinini F., Rovati L., Zanni A., Cagnacci A., Volpe A. and Facchinetti F.
INDIRECT EVIDENCE THAT ESTROGEN REPLACEMENT THERAPY STIMULATES NITRIC OXIDE SYNTHASE IN POSTMENOPAUSAL WOMEN.
Gynecol Endocrinol **14**, 142-146, **2000**
97. Rovati L.C., Setnikar I. and Genazzani A.R.
DOSE-RESPONSE EFFICACY OF A NEW ESTRADIOL TRANSDERMAL MATRIX PATCH FOR 7-DAY APPLICATION: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY.
Gynecol Endocrinol **14**, 282-291, **2000**
98. Matzinger D., Degen L., Drewe J., Meuli J., Duebendorfer R., Ruckstuhl N., D'Amato M., Rovati L.C. and Beglinger C.
THE ROLE OF LONG CHAIN FATTY ACIDS IN REGULATING FOOD INTAKE AND CHOLECYSTOKININ RELEASE IN HUMANS.
Gut **46**, 688-693, **2000**
99. Mauloni M., Rovati L.C., Cadossi R., de Terlizzi F., Ventura V., de Aloysio D.
MONITORING BONE EFFECT OF TRANSDERMAL HORMONE REPLACEMENT THERAPY BY ULTRASOUND INVESTIGATION AT THE PHALANX: A FOUR-YEAR FOLLOW-UP STUDY.
Menopause **7**, 402-412, **2000**
100. De Aloysio D., Rovati L.C., Giacobelli G., Setnikar I. and Bottiglioni F.
EFFICACY ON CLIMACTERIC SYMPTOMS AND SAFETY OF LOW DOSE ESTRADIOL TRANSDERMAL MATRIX PATCHES.
Arzneim.-Forsch. **50 (I)**, 293-300, **2000**
101. Stomati M., Monteleone P., Casarosa E., Quirici B., Puccetti S., Bernardi F., Genazzani A.D., Rovati L.C., Luici M., Genazzani A.R.
SIX-MONTH ORAL DEHYDROEPIANDROSTERONE SUPPLEMENTATION IN EARLY AND LATE POSTMENOPAUSE.
Gynecol. Endocrinol. **14**, 342-363, **2000**
102. Miglio F., Rovati L.C., Santoro A. and Setnikar I.
EFFICACY AND SAFETY OF ORAL BETAINE GLUCURONATE IN NON-ALCOHOLIC STEATOHEPATITIS.
Arzneim.-Forsch. **50 (II)**, 722-727, **2000**
103. Santoro A., Rovati L.C., Setnikar I., Caplain H. and Gualano V.
BIOAVAILABILITY AND PHARMACOKINETIC PROFILE OF GLYCERYL TRINITRATE

AND OF GLYCERYL DINITRATES DURING APPLICATION OF A NEW GLYCERYL TRINITRATE TRANSDERMAL PATCH.

Arzneim.-Forsch. 50 (II), 779-785, **2000**

104. Santoro A., Rovati L.C., Follet M., Setnikar I., Caplain H. and Gualano V. PLASMA LEVELS OF GLYCERYL TRINITRATE AND DINITRATES DURING APPLICATION OF THREE STRENGTHS OF A NEW GLYCERYL TRINITRATE TRANSDERMAL PATCH.

Arzneim.-Forsch. 50 (II), 786-794, **2000**

105. Santoro A., Rovati L.C., Lanzini R. and Setnikar I. PHARMACEUTICAL DEVELOPMENT AND CHARACTERISTICS OF A NEW GLYCERYL TRINITRATE TRANSDERMAL PATCH.

Arzneim.-Forsch. 50 (II), 897-903, **2000**

106. Reginster J.Y., Deroisy R., Rovati L.C., Lee R.L., Lejeune E., Bruyere O., Giacovelli G., Henrotin Y., Dacre J.E., Gossett C.

LONG-TERM EFFECTS OF GLUCOSAMINE SULPHATE ON OSTEOARTHRITIS PROGRESSION: A RANDOMISED, PLACEBO-CONTROLLED CLINICAL TRIAL. *Lancet 357*, 251-256, **2001**

107. Setnikar I., Schmid K., Rovati L.C., Vens-Cappell B., Mazur D. and Kozak I. BIOAVAILABILITY AND PHARMACOKINETIC PROFILE OF DIHYDROERGOTOXINE FROM A TABLET AND FROM AN ORAL SOLUTION FORMULATION.

Arzneim.-Forsch. 51 (I), 2-6, **2001**

108. Santoro A., Rovati L.C. and Setnikar I. ASSESSMENT OF SKIN SAFETY OF A NEW GLYCERYL TRINITRATE TRANSDERMAL PATCH.

Arzneim.-Forsch. 51 (I), 29-37, **2001**

109. Persiani S., D'Amato M., Makovec F., Arshad S.H., Holgate S.T. and Rovati L.C. PHARMACOKINETICS OF ANDOLAST AFTER ADMINISTRATION OF SINGLE ESCALATING DOSES OF INHALATION IN MILD ASTHMATIC PATIENTS.

Biopharm. Drug Dispos. 22, 73-81, **2001**

110. Vignon E., Garnerio P., Delmas P., Avouac B., Settica P., Boers M., Ehrlich E., MacKillop N. Rovati L.C., Serni U., Spector T. and Reginster J.Y.

RECOMMENDATIONS FOR THE REGISTRATION OF DRUGS USED IN THE TREATMENT OF OSTEOARTHRITIS: AN UPDATE ON BIOCHEMICAL MARKERS. *Osteoarthritis Cartilage 9*, 289-293, **2001**

111. Reginster J.Y., Rovati L.C. and Setnikar I. CORRECT REGIMEN OF FLUORIDE AND CALCIUM REDUCES THE RISK OF VERTEBRAL FRACTURES IN POSTMENOPAUSAL OSTEOPOROSIS.

Osteoporosis International 12, 800, **2001**

112. Ringe J.D. and Rovati L.C. TREATMENT OF OSTEOPOROSIS IN MEN WITH FLUORIDE ALONE OR IN COMBINATION WITH BISPHOSPHONATES.

Calcified Tissue Int. 69, 252-255, **2001**

113. Setnikar I. and Rovati L.C.
ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION OF
GLUCOSAMINE SULFATE.
Arzneim.-Forsch. 51 (I), 699-725, **2001**
114. Cagnacci A., Malmusi S., Arangino S., Zanni A., Rovati L.C., Cagnacci P. and Volpe
A.
INFLUENCE OF TRANSDERMAL ESTRADIOL IN THE REGULATION OF LEPTIN
LEVELS OF POSTMENOPAUSAL WOMEN: A DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY.
Menopause 9, 65-71, **2002**
115. Bruyere O., Honore A., Rovati L.C., Giacobelli G., Henrotin Y.E., Seidel L. and
Reginster J.Y.
RADIOLOGIC FEATURES POORLY PREDICT CLINICAL OUTCOMES IN KNEE
OSTEOARTHRITIS.
Scand. J. Rheumatol. 31, 13-16, **2002**
116. Persiani S., D'Amato M., Makovec F., Tavares I., Bishai P.M. and Rovati L.C.
PHARMACOKINETICS OF DEXLOXIGLUMIDE AFTER ADMINISTRATION OF
SINGLE AND REPEATED ORAL ESCLATING DOSES IN HEALTHY YOUNG MALES.

Int. J. Clinical Pharmacology and Therapeutics 40, 198-206, **2002**
117. Hidalgo L., Clavè P., Estorch M., Rodriguez-Espinosa J., Rovati L.C., Greeley Jr.
G.H., Capella G. and Lluís F.
EFFECT OF CHOLECYSTOKININ-A RECEPTOR BLOCKADE ON POSTPRANDIAL
INSULINAEMIA AND GASTRIC EMPTYING IN HUMANS.
Neurogastroenterol. Mot. 14, 519-525, **2002**
118. Pavelka K., Gatterova J., Olejarova M., Machacek S., Giacobelli G., and Rovati
L.C.
GLUCOSAMINE SULFATE USE AND DELAY OF PROGRESSION OF KNEE
OSTEOARTHRITIS.
Archives Internal Medicine 162, 2113-2123, **2002**
119. Bruyere O., Honore A., Ethgen O., Rovati L.C., Giacobelli G., Henrotin Y.E., Seidel
L. and Reginster J.Y.
CORRELATION BETWEEN RADIOGRAPHIC SEVERITY OF KNEE
OSTEOARTHRITIS AND FUTURE DISEASE PROGRESSION. RESULTS FROM A 3-
YEAR PROSPECTIVE, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFECT
OF GLUCOSAMINE SULFATE.
Osteoarthritis Cartilage 11, 1-5, **2003**
120. Bruyere O., Collette J.H., Ethgen O., Rovati L.C., Giacobelli G., Henrotin Y.E.,
Seidel L. and Reginster J.Y.
BIOCHEMICAL MARKERS OF BONE AND CARTILAGE REMODELING IN
PREDICTION OF LONGTERM PROGRESSION OF KNEE OSTEOARTHRITIS.
J. Rheumatology 30, 1043-1050, **2003**
121. Webber C., Roth A., Persiani S., Peard A.J., Makovec F., Rupil R.P., John B.A.,
Holding J.D., D'Amato M., Cybulski Z.R., Chasseaud L.F. and Rovati L.C.

- PHARMACOKINETICS AND METABOLISM OF THE CHOLECYSTOKININ ANTAGONIST DEXLOXIGLUMIDE IN MALE HUMAN SUBJECTS.
Xenobiotica **33**, 625-641, **2003**
122. Bruyere O., Henrotin Y.E., Honore A., Rovati L.C., Seidel L., Dardenne C. and Reginster J.Y.
IMPACT OF THE JOINT SPACE WIDTH MEASUREMENT METHOD ON THE DESIGN KNEE OSTEOARTHRITIS STUDIES.
Aging Clin. Exp. Res. **15**, 136-141, **2003**
123. Malesci A., Pezzilli R., D'Amato M. and Rovati L.C.
CCK-1 RECEPTOR BLOCKADE FOR TREATMENT OF BILIARY COLIC: A PILOT STUDY.
Aliment. Pharmacol. Ther. **18**, 333-337, **2003**
124. Genazzani A.D., Stomati M., Bernardi F., Piero M., Rovati L.C., Genazzani A.R.
LONG-TERM LOW-DOSE DEHYDROEPIANDROSTERONE ORAL SUPPLEMENTATION IN EARLY AND LATE POSTMENOPAUSAL WOMEN MODULATES ENDOCRINE PARAMETERS AND SYNTHESIS OF NEUROACTIVE STEROIDS.
Fertility and Sterility **80**, 1495-1501, **2003**
125. Pavelka K, Bruyere O, Rovati LC, Olejarova M, Giacovelli G, Reginster JY.
RELIEF IN MILD-TO-MODERATE PAIN IS NOT A CONFOUNDER IN JOINT SPACE NARROWING ASSESSMENT OF FULL EXTENSION KNEE RADIOGRAPHS IN RECENT OSTEOARTHRITIS STRUCTURE-MODIFYING DRUG TRIALS.
Osteoarthritis Cartilage **10**, 730-7, **2003**
126. Christgau S, Henrotin Y, Tanko LB, Rovati LC, Collette J, Bruyere O, Deroisy R, Reginster JY.
OSTEOARTHRITIC PATIENTS WITH HIGH CARTILAGE TURNOVER SHOW INCREASED RESPONSIVENESS TO THE CARTILAGE PROTECTING EFFECTS OF GLUCOSAMINE SULPHATE.
Clin Exp Rheumatol **22**, 36-42, **2004**
127. Bruyere O, Pavelka K, Rovati LC, Deroisy R, Olejarova M, Gatterova J, Giacovelli G, Reginster JY.
GLUCOSAMINE SULFATE REDUCES OSTEOARTHRITIS PROGRESSION IN POSTMENOPAUSAL WOMEN WITH KNEE OSTEOARTHRITIS: EVIDENCE FROM TWO 3-YEAR STUDIES.
Menopause **11**, 138-43, **2004**
128. Hall M, Persiani S, Cheung YL, Matthews A, Cybulski ZR, Holding JD, Kapil R, D'Amato M, Makovec F, Rovati LC.
INTERACTION OF DEXLOXIGLUMIDE, A CHOLECYSTOKININ TYPE-1 RECEPTOR ANTAGONIST, WITH HUMAN CYTOCHROMES P450.
Biopharm Drug Dispos **25**, 163-76, **2004**
129. Leardini G, Salaffi F, Caporali R, Canesi B, Rovati L, Montanelli R and the Italian Group for Study of the Costs of Arthritis (GISCA).
DIRECT AND INDIRECT COSTS OF OSTEOARTHRITIS OF THE KNEE.
Clin Exp Rheumatol **22**, 699-706, **2004**

130. Genazzani AR, Inglese S, Lombardi I, Pieri M, Bernardi F, Genazzani AD, Rovati L and Luisi M.
LONG-TERM LOW-DOSE DEHYDROEPIANDROSTERONE REPLACEMENT THERAPY IN AGING MALES WITH PARTIAL ANDROGEN DEFICIENCY.
The Aging Male **7**, 133-43, **2004**
131. Ringe JD, Dorst A, Faber H, Kipshoven C, Rovati LC, Setnikar I.
EFFICACY OF ETIDRONATE AND SEQUENTIAL MONOFLUOROPHOSPHATE IN SEVERE POSTMENOPAUSAL OSTEOPOROSIS: A PILOT STUDY.
Rheumatology Int **25**, 296-300, **2005**
132. Setnikar I, Senin P, Rovati LC.
ANTIATHEROSCLEROTIC EFFICACY OF POLICOSANOL, RED YEAST RICE EXTRACT, AND ASTAXANTHIN IN THE RABBIT.
Arzneimittel-Forschung **55**, 312-17, **2005**
133. Persiani S, Roda E, Rovati LC, Locatelli M, Giacovelli G, Roda A.
GLUCOSAMINE ORAL BIOAVAILABILITY AND PLASMA PHARMACOKINETICS AFTER INCREASING DOSES OF CRYSTALLINE GLUCOSAMINE SULFATE IN MAN.
Osteoarthritis Cartilage **13**, 1041-49, **2005**
134. Maheu E, Altman RD, Bloch DA, Doherty M, Mannoni A, Punzi L, Spector T, Verbruggen G, and the other members of the OARSI Hand OA Task Force: Carr A, Cicuttini F, Dreiser RL, Haraoui BP, Hart D, Pelletier JP, Ramonda R, Rovati L.
DESIGN AND CONDUCT OF CLINICAL TRIALS IN PATIENTS WITH OSTEOARTHRITIS OF THE HAND: RECOMMENDATIONS FROM A TASK FORCE OF THE OSTEOARTHRITIS RESEARCH SOCIETY INTERNATIONAL.
Osteoarthritis Cartilage **14**, 303-22, **2006**
135. Rovati LC, Pavelka K, Giacovelli G, Reginster JY.
ASSESSMENT OF JOINT SPACE NARROWING WITH CONVENTIONAL STANDING ANTERO-POSTERIOR RADIOGRAPHS: RELIEF IN MILD-TO-MODERATE PAIN IS NOT A CONFOUNDER IN RECENT OSTEOARTHRITIS STRUCTURE-MODIFYING DRUG TRIALS.
Osteoarthritis Cartilage **14 Suppl A**, A14-A18, **2006**
136. Herrero-Beaumont G, Rovati LC.
USE OF CRYSTALLINE GLUCOSAMINE SULFATE IN OSTEOARTHRITIS.
Future Rheumatology **1**, 397-414, **2006**
137. Persiani S, D'Amato M, Jakate A, Roy P, Wangsa J, Kapil R, Rovati LC.
PHARMACOKINETIC PROFILE OF DEXLOXIGLUMIDE.
Clin Pharmacokinet. **45**, 1177-88, **2006**
138. Roda A, Sabatini L, Barbieri A, Guardigli M, Locatelli M, Violante FS, Rovati LC, Persiani S.
DEVELOPMENT AND VALIDATION OF A SENSITIVE HPLC-ESI-MS/MS METHOD FOR THE DIRECT DETERMINATION OF GLUCOSAMINE IN HUMAN PLASMA.
J Chromatogr B Analyt Technol Biomed Life Sci. **844**, 119-26, **2006**

139. Cicero AFG, Rovati LC, Setnika I.
EULIPIDEMIC EFFECTS OF BERBERINE ADMINISTERED ALONE OR IN COMBINATION WITH OTHER NATURAL CHOLESTEROL-LOWERING AGENTS.
Arzneimittel-Forschung, *57*, 26-30, **2007**
140. Herrero-Beaumont G, Rovati LC, Castaneda S, Alvarez-Soria MA, Largo R.
THE REVERSE GLUCOSAMINE SULFATE PATHWAY: APPLICATION IN KNEE OSTEOARTHRITIS.
Expert Opin Pharmacother. *8*, 215-25, **2007**
141. Persiani S, Rotini R, Trisolino G, Rovati LC, Locatelli M, Paganini D, Antonioli D, Roda A.
SYNOVIAL AND PLASMA GLUCOSAMINE CONCENTRATIONS IN OSTEOARTHRITIC PATIENTS FOLLOWING ORAL CRYSTALLINE GLUCOSAMINE SULPHATE AT THERAPEUTIC DOSE.
Osteoarthr. Cartil. *15*, 764-72. **2007**
142. Bruyere O, Pavelka K, Rovati LC, Gatterova J, Giacobelli G, Olejarová M, Deroisy R, Reginster JY.
TOTAL JOINT REPLACEMENT AFTER GLUCOSAMINE SULFATE TREATMENT IN KNEE OSTEOARTHRITIS: RESULTS OF A MEAN 8-YEAR OBSERVATION OF PATIENTS FROM TWO PREVIOUS 3-YEAR, RANDOMISED, PLACEBO-CONTROLLED TRIALS.
Osteoarthr. Cartil. *16*, 254-60. **2008**
143. Malerba M, Mennuni L, Piepoli T, Caselli G, Makovec F, Rovati LC, D'Amato M, Ferrari F.
ANDOLAST ACTS AT DIFFERENT CELLULAR LEVELS TO INHIBIT IMMUNOGLOBULIN E SYNTHESIS.
Int J Immunopathol Pharmacol *22*, 85-94. **2009**
144. Piepoli T, Mennuni L, Zerbi S, Lanza M, Rovati LC, Caselli G.
GLUTAMATE SIGNALING IN CHONDROCYTES AND THE POTENTIAL INVOLVEMENT OF NMDA RECEPTORS IN CELL PROLIFERATION AND INFLAMMATORY GENE EXPRESSION.
Osteoarthritis Cartil. *17*, 1076-1083. **2009**
145. Bonn M, Eydeler U, Barkworth M, Rovati LC.
BIOEQUIVALENCE STUDY OF GENERIC TABLET FORMULATIONS CONTAINING ETHINYLESTRADIOL AND CHLORMADINONE ACETATE IN HEALTHY FEMALE VOLUNTEERS.
Arzneimittelforschung; *59*: 651-658. **2009**
146. Pastorini E, Rotini R, Guardigli M, Vecchiotti S, Persiani S, Trisolino G, Antonioli D, Rovati LC, Roda A.
DEVELOPMENT AND VALIDATION OF A HPLC-ES-MS/MS METHOD FOR THE DETERMINATION OF GLUCOSAMINE IN HUMAN SYNOVIAL FLUID.
J Pharm Biomed Anal. *50*:1009-14. **2009**
147. Persiani S, Matthews A, Larger P, Hall M, Rotini R, Trisolino G, Antonioli D, Zaccarelli L, Rovati LC.
GLUCOSAMINE BINDING TO PROTEINS IN PLASMA AND SYNOVIAL FLUID AND

- BLOOD CELL/PLASMA PARTITIONING IN MOUSE AND MAN IN VITRO.
Drug Metabol Drug Interact, 24: 211-227. **2009**
148. Persiani S, Canciani L, Larger P, Rotini R, Trisolino G, Antonioli D, Rovati LC. IN VITRO STUDY OF THE INHIBITION AND INDUCTION OF HUMAN CYTOCHROMES P450 BY CRYSTALLINE GLUCOSAMINE SULFATE.
Drug Metabol Drug Interact, 24:195-209. **2009**
149. Letari O, Booth C, Bonazzi A, Garofalo P, Makovec F, Rovati LC, Caselli G. EFFICACY OF CR3294, A NEW BENZAMIDINE DERIVATIVE, IN THE PREVENTION OF 5-FLUOROURACIL-INDUCED GASTROINTESTINAL MUCOSITIS AND DIARRHEA IN MICE.
Cancer Chemother Pharmacol., 66: 819-27. **2010**
150. Bruyere O, Kanis JA, Ibar-Abadie ME, Alsayed N, Brandi ML, Burllet N, Cahall DL, Chines A, Devogelaer JP, Dere W, Goel N, Hughes N, Kaufman JM, Korte S, Mitlak BH, Niese D, Rizzoli R, Rovati LC, Reginster JY.
THE NEED FOR A TRANSPARENT, ETHICAL, AND SUCCESSFUL RELATIONSHIP BETWEEN ACADEMIC SCIENTISTS AND THE PHARMACEUTICAL INDUSTRY: A VIEW OF THE GROUP FOR THE RESPECT OF ETHICS AND EXCELLENCE IN SCIENCE (Grees).
Osteoporosis Int, 21: 713-722. **2010**
151. Giacobelli G., Rovati L.C.
GLUCOSAMINE AND OSTEOARTHRITIS. CONCLUSIONS NOT SUPPORTED BY METHODS AND RESULTS.
BMJ, 341: c6338. doi: 10.1136/bmj.c6338. **2010**
152. Scholtissen S, Bruyere O, Neuprez A, Severens JL, Herrero-Beaumont G, Rovati L, Hilingsmann M, Reginster JY.
GLUCOSAMIN SULPHATE IN THE TREATMENT OF KNEE OSTEOARTHRITIS: COST-EFFECTIVENESS COMPARISON WITH PARACETAMOL.
Int J Clin Practice, 64: 756-62. **2010**
153. Jordan JM, Sowers MF, Messier SP, Bradley J, Arangio G, Katz JN, Losina E, Rovati L, Bachtell N, Cooper C, Spector T, Zhang W, Gardiner J, Wahba M. METHODOLOGIC ISSUES IN CLINICAL TRIALS FOR PREVENTION OR RISK REDUCTION IN OSTEOARTHRITIS.
Osteoarthritis Cartil., 19: 500-508. **2011**
154. Pastorini E, Vecchiotti S, Colliva C, Persiani S, Rotini R, Roatti G, Zaccarelli L, Rovati LC, Roda A.
IDENTIFICATION AND QUANTIFICATION OF GLUCOSAMINE IN RABBIT CARTILAGE AND CORRELATION WITH PLASMA LEVELS BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY-ELECTROSPRAY IONIZATION-TANDEM MASS SPECTROMETRY.
Analytica Chimica Acta, 695: 77-83. **2011**
155. Palma Dos Reis R, Giacobelli G, Girolami F, André R, Bonazzi A, Rovati LC. CRYSTALLINE GLUCOSAMINE SULFATE IN THE TREATMENT OF OSTEOARTHRITIS: EVIDENCE OF LONG-TERM CARDIOVASCULAR SAFETY

FROM CLINICAL TRIALS.

Open Rheumatol J, 5: 69-77. **2011**.

156. Chiusaroli R, Piepoli T, Zanelli T, Ballanti P, Lanza M, Rovati LC, Caselli G. EXPERIMENTAL PHARMACOLOGY OF GLUCOSAMINE SULFATE. *Int J Rheumatol*, 2011. **2011**. Epub 2011 Oct 9.
157. Gossec L, Paternotte S, Bingham CO 3rd, Clegg DO, Coste P, Conaghan PG, Davis AM, Giacobelli G, Gunther KP, Hawker G, Hochberg MC, Jordan JM, Katz JN, Kloppenburg M, Lanzarotti A, Lim K, Lohmander LS, Mahomed NN, Maillefert JF, Manno RL, March LM, Mazzuca SA, Pavelka K, Punzi L, Roos EM, Rovati LC, Shi H, Singh JA, Suarez-Almazor ME, Tajana-Messi E, Dougados M; OARSI-OMERACT Task Force
TOTAL ARTICULAR REPLACEMENT AS OUTCOME MEASURE IN OA. OARSI/OMERACT INITIATIVE TO DEFINE STATES OF SEVERITY AND INDICATION FOR JOINT REPLACEMENT IN HIP AND KNEE OSTEOARTHRITIS. AN OMERACT 10 SPECIAL INTEREST GROUP.
J Rheumatol, 38:1765-9. **2011**.
158. Berenbaum F, Grifka J, Cazzaniga S, D'Amato M, Giacobelli G, Chevalier X, Rannou F, Rovati LC, Maheu E.
A RANDOMISED, DOUBLE-BLIND, CONTROLLED TRIAL COMPARING TWO INTRA-ARTICULAR HYALURONIC ACID PREPARATIONS DIFFERING BY THEIR MOLECULAR WEIGHT IN SYMPTOMATIC KNEE OSTEOARTHRITIS.
Ann Rheum Dis, 71:1454-60. **2012**
159. Manno RL, Bingham CO 3rd, Paternotte S, Gossec L, Halhol H, Giacobelli G, Rovati L, Mazzuca SA, Clegg DO, Shi H, Tajana Messi E, Lanzarotti A, Dougados M. OARSI-OMERACT INITIATIVE: DEFINING THRESHOLDS FOR SYMPTOMATIC SEVERITY AND STRUCTURAL CHANGES IN DISEASE MODIFYING OSTEOARTHRITIS DRUG (DMOAD) CLINICAL TRIALS.
Osteoarthritis Cartilage, 20:93-101. **2012**
160. Bruyère O, Avouac B, Richette P, Maheu E, Bruel P, Coxam V, Guillou GB, Lugin AE, Merceron C, Pauquai T, Rannou F, Ythier-Moury P, Tsouderos Y, Urban N, Rovati L, Guicheux J, Reginster JY.
HEALTH CLAIMS ASSESSMENT IN THE FIELD OF JOINT AND CARTILAGE: A CONSENSUS VIEWPOINT OF THE GROUP FOR THE RESPECT OF ETHICS AND EXCELLENCE IN SCIENCE .
Curr Med Res Opin, 28:611-6. **2012**.
161. Rovati LC, Girolami F, Persiani S.
CRYSTALLINE GLUCOSAMINE SULFATE IN THE MANAGEMENT OF KNEE OSTEOARTHRITIS: EFFICACY, SAFETY, AND PHARMACOKINETIC PROPERTIES.
Ther Adv Musculoskelet Dis, 4:167-80. **2012**
162. Hadji P, Biskup J, Boekhoff J, Ziller M, Bonn M, Rovati L.
EVALUATION OF EFFICACY, SAFETY AND EFFECTS ON SYMPTOMS OF ANDROGENIZATION OF A GENERIC ORAL CONTRACEPTIVE CONTAINING CHLORMADINONE ACETATE 2 MG/ETHINYLESTRADIOL 0.03 MG.
Contraception. Mar 23. [Epub ahead of print] PubMed PMID: 22445436. **2012**

163. Reddy KR, Belle SH, Fried MW, Afdhal N, Navarro VJ, Hawke RL, Wahed AS, Doo E, Meyers CM; SyNCH Study Group.
RATIONALE, CHALLENGES, AND PARTICIPANTS IN A PHASE II TRIAL OF A BOTANICAL PRODUCT FOR CHRONIC HEPATITIS C.
Clin Trials, 9:102-12. **2012**
164. Mariño Z, Crespo G, D'Amato M, Brambilla N, Giacobelli G, Rovati L, Costa J, Navasa M, Forn X.
INTRAVENOUS-SILIBININ MONOTHERAPY SHOWS SIGNIFICANT ANTIVIRAL ACTIVITY IN HCV-INFECTED PATIENTS IN THE PERI-TRANSPLANTATION PERIOD.
J Hepatol, 58:415-20. **2013**
165. Persiani S, Sala F, Cole R, Webber G, Caselli G, Vaghi P, Rovati LC.
SILIBININ HEMISUCCINATE BINDING TO PROTEINS IN PLASMA AND BLOOD CELL/PLASMA PARTITIONING IN MOUSE, RAT, DOG AND MAN IN VITRO.
Drug Metabol Drug Interact, 28:115-22. **2013**
166. Chiusaroli R, Visentini M, Galimberti C, Casseler C, Mennuni L, Covaceuszach S, Lanza M, Ugolini G, Rovati LC, Visintin M.
TARGETING OF ADAMTS5'S ANCILLARY DOMAIN WITH THE RECOMBINANT MAB CRB0017 AMELIORATES DISEASE PROGRESSION IN A SPONTANEOUS MURINE MODEL OF OSTEOARTHRITIS.
Osteoarthritis Cartilage, 21:1807-10. **2013**
167. Hiligsmann M, Cooper C, Arden N, Boers M, Branco JC, Luisa Brandi M, Bruyère O, Guillemin F, Hochberg MC, Hunter DJ, Kanis JA, Kvien TK, Laslop A, Pelletier JP, Pinto D, Reiter-Niesert S, Rizzoli R, Rovati LC, Severens JL, Silverman S, Tsouderos Y, Tugwell P, Reginster JY.
HEALTH ECONOMICS IN THE FIELD OF OSTEOARTHRITIS: AN EXPERT'S CONSENSUS PAPER FROM THE EUROPEAN SOCIETY FOR CLINICAL AND ECONOMIC ASPECTS OF OSTEOPOROSIS AND OSTEOARTHRITIS (ESCEO).
Semin Arthritis Rheum, 43:303-13. **2013**
168. Martelli A, Testai L, Anzini M, Cappelli A, Di Capua A, Biava M, Poce G, Consalvi S, Giordani A, Caselli G, Rovati L, Ghelardini C, Patrignani P, Sautebin L, Breschi MC, Calderone V.
THE NOVEL ANTI-INFLAMMATORY AGENT VA694, ENDOWED WITH BOTH NO-RELEASING AND COX2-SELECTIVE INHIBITING PROPERTIES, EXHIBITS NO-MEDIATED POSITIVE EFFECTS ON BLOOD PRESSURE, CORONARY FLOW AND ENDOTHELIUM IN AN EXPERIMENTAL MODEL OF HYPERTENSION AND ENDOTHELIAL DYSFUNCTION.
Pharmacol Res, **2013** Sep 29;78C:1-9. doi: 10.1016/j.phrs.2013.09.008. [Epub ahead of print]
169. Sala F, Albares P, Colovic M, Persiani S, Rovati LC.
DEVELOPMENT AND VALIDATION OF TWO LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY METHODS FOR THE DETERMINATION OF SILIBININ AND SILIBININ HEMISUCCINATE IN HUMAN PLASMA.
J Chromatogr B Analyt Technol Biomed Life Sci. 945-946:1-9. **2014**.

170. Rendina M, D'Amato M, Castellaneta A, Castellaneta NM, Brambilla N, Giacobelli G, Rovati L, Rizzi SF, Zappimbulso M, Bringiotti RS, Di Leo A.
ANTIVIRAL ACTIVITY AND SAFETY PROFILE OF SILIBININ IN HCV PATIENTS WITH ADVANCED FIBROSIS AFTER LIVER TRANSPLANTATION: A RANDOMIZED CLINICAL TRIAL.
Transpl Int. 27:696-704. **2014**
171. Hiligsmann M, Cooper C, Guillemin F, Hochberg MC, Tugwell P, Arden N, Berenbaum F, Boers M, Boonen A, Branco JC, Maria-Luisa B, Bruyère O, Gasparik A, Kanis JA, Kvien TK, Martel-Pelletier J, Pelletier JP, Pinedo-Villanueva R, Pinto D, Reiter-Niesert S, Rizzoli R, Rovati LC, Severens JL, Silverman S, Reginster JY.
A REFERENCE CASE FOR ECONOMIC EVALUATIONS IN OSTEOARTHRITIS: AN EXPERT CONSENSUS ARTICLE FROM THE EUROPEAN SOCIETY FOR CLINICAL AND ECONOMIC ASPECTS OF OSTEOPOROSIS AND OSTEOARTHRITIS (ESCEO).
Semin Arthritis Rheum. Jun 27. pii: S0049-0172(14)00161-9. **2014**
172. Persiani S, Sala F, Manzotti C, Colovic M, Donazzolo Y, Barbetta B, Vitalini C, Giacobelli G, Benvenuti C, Rovati LC.
EFFECT OF A COMBINATION OF BERBERINE AND MONACOLIN ON CYP ENZYMES: AN ORAL COCKTAIL INTERACTION STUDY IN HEALTHY VOLUNTEERS.
J Pharmacy and Pharmacol. 2:660-68. **2014**
173. Malerba M, D Amato M, Radaeli A, Giacobelli G, Rovati L, Arshad SH, Holgate ST.
EFFICACY OF ANDOLAST IN MILD TO MODERATE ASTHMA: A RANDOMIZED, CONTROLLED, DOUBLE-BLIND MULTICENTER STUDY (THE ANDAST TRIAL).
Curr Pharm Des. 21:3835-43. **2015**
174. Valacchi G, Grisci G, Sticozzi C, Lim Y, Paolino M, Giuliani G, Mendichi R, Belmonte G, Artusi R, Zanardi A, Garofalo P, Giorgi G, Cappelli A, Rovati LC.
WOULD HEALING PROPERTIES OF HYALURONAN DERIVATIVES BEARING FERULATE RESIDUES.
J Mater. Chem. B. 3:7037-45. **2015**
175. Arden N, Richette P, Cooper C, Bruyère O, Abadie E, Branco J, Brandi ML, Berenbaum F, Clerc C, Dennison E, Devogelaer JP, Hochberg M, D'Hooghe P, Herrero-Beaumont G, Kanis JA, Laslop A, Leblanc V, Maggi S, Mautone G, Pelletier JP, Petit-Dop F, Reiter-Niesert S, Rizzoli R, Rovati L, Tajana Messi E, Tsouderos Y, Martel-Pelletier J, Reginster JY.
CAN WE IDENTIFY PATIENTS WITH HIGH RISK OF OSTEOARTHRITIS PROGRESSION WHO WILL RESPOND TO TREATMENT? A FOCUS ON BIOMARKERS AND FRAILITY.
Drugs Aging. 32:525-35. **2015**
176. Rosso N, Marin V, Giordani A, Persiani S, Sala F, Cavicchioli L, Rovati LC, Tiribelli C.
THE PROS AND THE CONS FOR THE USE OF SILYBIN-RICH ORAL

FORMULATIONS IN TREATMENT OF LIVER DAMAGE (NAFLD IN PARTICULAR).
Curr Med Chem;22:2954-71. **2015**

177. Persiani S, Sala F, Manzotti C, Colovic M, Zangarini M, Donazzolo Y, Barbetta B, Vitaliani C, Giacobelli G, Benvenuti C, Rovati LC.
EVALUATION OF LEVOTHYROXINE BIOAVAILABILITY AFTER ORAL
ADMINISTRATION OF A FIXED COMBINATION OF SOY ISOFLAVONES IN POST-
MENOPAUSAL FEMALE VOLUNTEERS.
Drug Res (Stuttg);66(3):136-40. **2016**.
178. Lobo B, Serra J, D'Amato M, Rovati L, Malagelada JR, Santos J, Azpiroz F.
SELECTIVE CCK(1) RECEPTOR ANTAGONISM ENHANCES ACCOMMODATION
AND TOLERANCE OF INTESTINAL GAS IN FUNCTIONAL GUT DISORDERS.
J Gastroenterol Hepatol; 31:288-93. **2016**
179. Rovati LC, Girolami F, D'Amato M, Giacobelli G.
EFFECTS OF GLUCOSAMINE SULFATE ON THE USE OF RESCUE NON-
STEROIDAL ANTI-INFLAMMATORY DRUGS IN KNEE OSTEOARTHRITIS:
RESULTS FROM THE PHARMACO-EPIDEMIOLOGY OF GONARTHROSIS
(PEGASUS) STUDY.
Semin Arthritis Rheum;45(4 Suppl):S34-41. **2016**
180. Runhaar J, Deroisy R, van Middelkoop M, Barretta F, Barbetta B, Oei EH,
Vroegindeweyj D, Giacobelli G, Bruyère O, Rovati LC, Reginster JY, Bierma-
Zeinstra SM.
THE ROLE OF DIET AND EXERCISE AND OF GLUCOSAMINE SULFATE IN THE
PREVENTION OF KNEE OSTEOARTHRITIS: FURTHER RESULTS FROM THE
PREVENTION OF KNEE OSTEOARTHRITIS IN OVERWEIGHT FEMALES (PROOF)
STUDY.
Semin Arthritis Rheum; 45(4 Suppl):S42-8. **2016**
181. Comi E, Lanza M, Ferrari F, Mauri V, Caselli G, Rovati LC.
EFFICACY OF CR4056, A FIRST-IN-CLASS IMIDAZOLINE-2 ANALGESIC DRUG,
IN COMPARISON WITH NAPROXEN IN TWO RAT MODELS OF
OSTEOARTHRITIS.
J Pain Res; 10:1033-43. **2017**
182. Caselli G, Bonazzi A, Lanza M, Ferrari F, Maggioni D, Ferioli C, Giambelli R, Comi
E, Zerbi S, Perrella M, Letari O, Di Luccio E, Colovic M, Persiani S, Zanelli T,
Mennuni L, Piepoli T, Rovati LC.
PHARMACOLOGICAL CHARACTERISATION OF CR6086, A POTENT
PROSTAGLANDIN E(2) RECEPTOR 4 ANTAGONIST, AS A NEW POTENTIAL
DISEASE-MODIFYING ANTI-RHEUMATIC DRUG.
Arthritis Res Ther; 20:39. **2018**

PUBLICATIONS

Book chapters

1. Makovec F, Rovati LA, Rovati LC, Setnikar I.
STIMULATION OF GASTROPROTECTIVE MUCUS BY PROGLUMIDE.
In: Proceedings of the 6th International Symposium on Proglumide, I. Setnikar ed., XII and V International Gastroenterology and Endoscopy Congresses, RRL publ., p. 67-76, 1984.
2. Rovati LC, Sacerdote P, Panerai AE.
EFFECTS OF PROGLUMIDE ON MORPHINE ANALGESIA AND TOLERANCE.
In: Neuronal Cholecystokinin. J.J. Vanderhaeghen and J.N. Crawley eds., Annals of the New York Academy of Sciences, Vol. 448, p. 630-632, New York, 1985.
3. Panerai AE, Sacerdote P, Brini A, Bianchi M, Rovati LC, Cocco E.
PERIPHERAL NERVE DEAFFERENTATION AFFECTS BRAIN AND SPINAL CORD NEUROPEPTIDES: LATERALIZATION AND PHARMACOLOGICAL TREATMENTS.

In: Advances in Pain Research and Therapy, Vol. 10. M. Tiengo ed., Raven Press, New York, p. 157-168, 1987.
4. Rovati LC, Bani M, Makovec F, Revel L, Setnikar I.
LORGLUMIDE AND LOXIGLUMIDE: TWO POTENT AND SPECIFIC ANTAGONISTS OF PERIPHERAL CCK.
In: Gastrin and Cholecystokinin. Chemistry, Physiology and Pharmacology. J.P. Bali and J. Martinez eds., Elsevier, Amsterdam, p. 45-48, 1987.
5. Rovati LC, Makovec F.
NEW PENTANOIC ACID DERIVATIVES WITH POTENT CCK ANTAGONISTIC PROPERTIES: DIFFERENT ACTIVITY ON THE PERIPHERY VS. CENTRAL NERVOUS SYSTEM.
In: Cholecystokinin Antagonists. R.Y. Wang and R. Schoenfeld eds., Alan R. Liss Inc., New York, p. 1-11, 1988.
6. Rovati LC.
PENTANOIC ACID DERIVATIVES.
In: Cholecystokinin Antagonists in Gastroenterology. G. Adler and C. Beglinger eds, Springer-Verlag, Berlin-Heidelberg, p. 65-69, 1991.

7. De Giorgio R., Stanghellini V, Ricci Maccarini M, Morselli-Labate AM, Barbara G, Franzoso L, Rovati LC, Corinaldesi R, Barbara L, Go VLW.
EFFECTS OF DIETARY FAT ON POSTPRANDIAL GASTROINTESTINAL MOTILITY ARE INHIBITED BY A CHOLECYSTOKININ TYPE A RECEPTOR ANTAGONIST.
In: Cholecystokinin. Annals of the New York Academy of Sciences, Vol. 713, p. 226-231, New York, 1994.
8. Mesquita MA, Thompson DG, Ahluwalia NK, Troncon LEA, D'Amato M, Rovati LC.
ROLE OF CCK IN THE REGULATION OF DYNAMIC AND TONIC MECHANICAL RESPONSE OF THE HUMAN GASTRIC FUNDUS TO LIPIDS.
In: Cholecystokinin. Annals of the New York Academy of Sciences, Vol. 713, p. 393-394, New York, 1994.
9. Rovati LC, D'Amato M, Peris W, Revel L, Makovec F.
SELECTIVITY AND POTENCY OF NEW BASIC CCK-B ANTAGONISTS.
In: Cholecystokinin. Annals of the New York Academy of Sciences, Vol. 713, p. 395-397, New York, 1994.
10. Cann PA, Rovati LC, Smart HL, Spiller RC, Whorwell PJ.
LOXIGLUMIDE, A CCK-A ANTAGONIST, IN IRRITABLE BOWEL SYNDROME.
In: Cholecystokinin. Annals of the New York Academy of Sciences, Vol. 713, p. 449-450, New York, 1994.
11. Chua ASB, Bekkering M, Rovati LC, Keeling PWN.
CLINICAL EFFICACY AND PROKINETIC EFFECT OF THE CCK-A ANTAGONIST LOXIGLUMIDE IN NONULCER DYSPEPSIA.
In: Cholecystokinin. Annals of the New York Academy of Sciences, Vol. 713, p. 451-453, New York, 1994.
12. Rovati L.C.
NUOVE FRONTIERE FARMACOLOGICHE NELLA TERAPIA ORMONALE SOSTITUTIVA.
In: Menopausa 2000. Menopausa e terapia ormonale sostitutiva: ipotesi per una consensus conference italiana. L. Zichella (Ed.). A.B.E. pubbl., p. 68-74, 1995.
13. D'Amato M., Makovec F., Rovati L.C.
CCK_A RECEPTORS IN GASTROINTESTINAL DISORDERS.
In: Drug Development: Molecular Targets for GI Diseases. T.S. Gaginella and A. Guglietta (Ed.). Humana Press Inc., Totowa NJ, p. 147-176, 1999.
14. Rovati L.C.
HRT: RISCHIO ONCOLOGICO MAMMARIO - TERAPIA TRANSDERMICA?
In: Ginecologia della terza età, V Congresso Nazionale SIGITE, Portoferraio 12-15 settembre 2000. CIC Edizioni Internazionali, p. 324-328, 2000.
15. Gagnatelli A., Rovati L.C.
VALIDITA' DELLA VALUTAZIONE DEL PROFILO ORMONALE NELLO SCREENING DI PAZIENTI IN MENOPAUSA CANDIDATE A TERAPIA ORMONALE SOSTITUTIVA.
In: Menopausa 2001, 8° Congresso Nazionale della Società Italiana della

Menopausa, Pisa 14-17 giugno 2001. CIC Edizioni Internazionali, p. 343-346, 2001.